Jobs
View more job listings or post a job
Gate Bioscience Director of Toxicology
Nura Bio Director of Toxicology
Nura Bio Vice President of CMC
MilliporeSigma Emerging Biotech Market Development Manager - San Fransisco
How Cancer LLC Social Media Digital Marketing Specialist  
How Cancer LLC Syndicated National Writer - Cancer 
University of California, Davis SCREENING SUPERVISOR
InnoAlliance Scientist/Sr Scientist of Bioanalysis & Biomarkers
Post a job

Workshop

[In-Person] Preclinical Development and IND Filing for Antibody-Based Therapeutics: Nuts, Bolts and Best Practices


Speakers: Laurence Fayadat-Dilman (Merck and Co), Keegan Cooke (Amgen), Jay Tibbitts (Surrozen), Robert Caldwell (AbbVie), Lilia Koriazova (Erasca), Sara Glickstein Bar-Zeev (Genentech); Key Kang (Genentech), Arianne L. Motter (FDA)
Organizers: Ayse Meric Ovacik (Genentech); Smita Salian-Mehta (Gilead); Isabel Figueroa Amenabar (Amgen); Laurence Fayadat-Dilman (Merck and Co); Minli Xie (Erasca); Snow Ge (Biobridge Pharma); Shichang Miao (Amgen)
Date: 2023-05-24
Time: 8:45-17:25 Pacific Time
Registration fee: Regular attendees: $295; Academic/Students/Postdocs: $125; Major Sponsorship: $3000; Vendor Show: $695; On-site Registration:$500
Location: Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor: (2).; Veloxity Labs
Vendor show vendors registered to date: (23)Abzena; Alturas Analytics; Biointron; BioTether Sciences; Charles River Labs; CHIRON Recombinant Proteins; Correlia Biosystems Inc; CP Lab Safety; Ellegaard BioResearch; Emery Pharma; Frontage Laboratories; Gator Bio; GBI Bio; Inotiv; IRBM; KCAS Bio; Meadowhawk Biolabs; Medicilon; MilliporeSigma; Novogene Corporation Inc.; Q2Lab Solutions; QPS LLC; WuXi AppTec
Registration: http://www.PBSS.org
Registration deadline:2023-05-23  (it will close sooner if the seating cap is reached)

About the Topic

Commercial clinical pipeline of mAbs has vastly increased in recent years; the mAbs based therapeutics in development has been growing at an incredible pace. The investigational new drug application (IND) application is an important step to achieve in mAb based therapeutics, and understanding the requirements for a successful IND filing is utmost important to ensure fast and efficient development. While the principles and basics are similar across different modalities for an IND filing such as safety studies, there are important aspects that need to be considered for mAb based therapeutics. In this workshop, we will cover the best practices for a successful IND package of mAbs. Our highly experienced speakers will discuss the preclinical studies for mAb based therapeutics IND packages. This workshop will be suitable for novice drug developers and small molecule drug development experts who are interested in mAb therapeutic development.

Topics to be covered:

  • Overview of preclinical development and IND filing requirements for antibody-based therapeutics
  • Required preclinical studies for
    Safety assessment
    Pharmacology
    Pharmacokinetics
    CMC (Chemistry, Manufacturing, Control)
  • Clinical development plans
  • FDA’s perspective by an FDA reviewer

 

Time (PT)

Topic

Presenter

8:45-9:00 am

PBSS Welcome and Introduction 

Snow Ge (BridgeBio Pharma)

9:00-9:20 am

1. Overview of preclinical development and IND filing requirements for antibody-based therapeutics

Ayse Meric Ovacik, PhD, Senior Principal Scientist, Genentech

9:20-9:50 am

2. Overview of antibody-based therapeutics: structure, generation, design, and optimization

Laurence Fayadat-Dilman, PhD, Executive Director, Discovery Biologics, Merck & Co, Inc.

9:50-10:25 am

3- Non-clinical pharmacology considerations for bi-specific antibodies

Keegan Cooke, BA, Principal Scientist

Oncology Research, Amgen

10:25-10:35 am

Major Sponsor’s Presentation

Mycenax Biotech Inc. 

10:35-10:50am

Break Period & Vendor Show

-

10:50-11:45am

4- Pharmacokinetic/Pharmacodynamic and bioanalytical considerations for successful IND filings

Jay Tibbitts, DVM, PhD, Vice President Non-Clinical Development, Surrozen

11:45-12:35pm

Lunch

Sponsor: Pharmaron

12:35-1:45pm

5- Preclinical toxicology points to consider for biotherapeutic IND submissions

Robert Caldwell, PhD, Senior Principal Research Scientist, Toxicology, AbbVie

1:45-2:45pm

6. IND-enabling CMC activities for therapeutic antibodies

 

Lilia Koriazova, PhD, Sr. Director, Biologics Pharmaceutical Sciences, R&D department, Erasca

2:45-2:55pm

Major Sponsor’s Presentation

Veloxity Labs

2:55-3:10pm

Break

-

3:10-3:45pm

7- Clinical Development Plan

Sara Glickstein Bar-Zeev, PhD, Senior Clinical Scientist, Genentech

3:45-4:15pm

8. Regulatory strategies and Interactions with FDA: Industry perspective & how to prepare for FDA meetings 

Key Kang, MSc, Global Regulatory Leader and Group Director, Genentech Inc.

4:15-4:50pm

9- INDs for biologics: The regulatory perspective

Arianne Motter, PhD, DABT, Senior Toxicologist/CDER/OND/DPT-ID, U.S FDA

4:50-5:25pm

Panel Discussion

All Speakers

5:25-6:25pm

Happy Hour

Sponsor: Alturas Analytics

 


2025-02-13, [Free Online] The Science and Stories of Promising Biotech Startups
2025-02-26, [In-Person] Demystifying Biopharma Business Development: Understanding the Process and Thriving as a BD Professional
2025-03-07, [In-Person] Clinical Trial Planning and Conduct: Fundamentals, Strategies and Best Practices
2025-03-27, [Free Online Workshop] Biotech Financing 101: from Angels, Government Agencies, Foundations and VCs
2025-04-01, [For vendors ONLY] Seattle PBSS Seminar Luncheon Vendor Show
2025-04-09, [In-Person] Cell Therapy Discovery and Development: Fundamentals, Strategies and Best Practices (jointly by PBSS and RAPS-SF)
2025-04-22, [Free Online Workshop] Career Transitions for Research Scientists: BD/Sales in CROs, CDMOs, and Lab Products & Instruments
2025-04-25, [In-Person] Drug Metabolism Fundamentals and Metabolite Identification
2025-05-05, [Free Online] Highlights of 2024 FDA Drug Approvals
2025-05-12, [In-Person] Preclinical Pharmacology Studies and Translational Medicine for Drug Discovery and Development
2025-06-02, [In-Person] Metabolism and Transport-mediated Drug-Drug Interaction: Current Practices, Regulatory Guidances, and Their Impact on Drug Development
©Pharmaceutical & BioScience Society, International; Last Modified: 2/12/2025; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Allucent Experts bringing development innovation w/ClinPharm Modeling & Simulation deliverables to inform dose, study design, modeling+development strategies.
Alturas Analytics, Inc. Expert Regulated & Non-Regulated LC-MS, GC-MS bioanalytical & PK/TK analysis of small & large molecules in any matrix. Discovery through phase IV.
Hypha Discovery Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
Submit a Text Ad